Hugel Reports Impressive First-Half Financial Results
Hugel Inc., a leading global company in the medical aesthetics field, has announced outstanding financial results for the first half of the year. The company's net sales have soared past KRW 200 billion, with Q2 alone recording net sales of KRW 110.3 billion.
Strong Growth in Key Products
The success in their financial performance this quarter can be attributed to incredible growth in key product lines, including botulinum toxin and hyaluronic acid fillers. In the second quarter, Hugel experienced a 15.5% rise in net sales compared to the same period last year, highlighting the demand for their innovative products.
Overseas Market Expansion
Hugel's expansion into overseas markets has significantly influenced their sales growth. The U.S. launch of their botulinum toxin and increased shipments into new markets have driven impressive revenue outcomes. This strategy has resulted in a fantastic 21% increase in overseas net sales to KRW 69.8 billion, accounting for 63% of total quarterly sales.
Record-High Quarterly Figures
For the first time, Hugel has reached cumulative net sales and operating profits exceeding KRW 200 billion and KRW 95 billion, respectively, solidifying its position as a heavyweight in the medical aesthetics landscape.
Noteworthy Product Performance
One of Hugel's standout performers is their botulinum toxin, known in local markets as Botulax and globally as Letybo. This key product garnered KRW 61.2 billion in net sales for Q2, marking a 20% increase from the previous year. As a result, Hugel achieved over KRW 100 billion in cumulative sales during the first half.
Cosmetics: A New Growth Engine
Hugel's cosmetics line, including brands such as WELLAGE and BYRYZN, has shown remarkable growth, with a staggering 104.5% year-on-year increase, reaching KRW 13.6 billion. This expansion showcases Hugel's versatility and ability to innovate in the beauty and aesthetics market.
Future Outlook
Looking ahead, Hugel plans to leverage its quality products and competitive edge in the U.S. market while maintaining a strong presence in Asia and expanding into the Middle East and emerging countries. This strategy positions Hugel for continuous growth as it sets its sights on further market penetration.
About Hugel
Hugel Inc. was established in 2001 and has quickly risen to prominence as a global leader in medical aesthetics. The company specializes in injectable solutions for skin rejuvenation, including botulinum toxin, hyaluronic acid fillers, and skin boosters. Hugel is proud to be the only South Korean company with regulatory approvals in the U.S., China, and Europe, which underscores its expertise and reputation in the industry.
With a commitment to innovation, safety, and quality, Hugel continues to grow and expand its presence, now serving approximately 70 countries through nine global subsidiaries across major regions. As the medical aesthetics industry evolves, Hugel is poised to lead with promising developments and consumer-focused solutions.
For any inquiries, please contact:
Jihyun Kim, Manager of the PR Team, Hugel
jihyun.kim@hugel-inc.com
Frequently Asked Questions
What financial milestones did Hugel achieve in H1 2025?
Hugel exceeded net sales of KRW 200 billion and operating profit of KRW 95 billion during the first half of 2025.
What products contributed to Hugel's growth?
The growth was driven by botulinum toxin and hyaluronic acid fillers, along with a substantial increase in cosmetics sales.
Which markets are key for Hugel's expansion?
Hugel is focusing on deepening its market presence in the U.S., China, the Middle East, and other emerging markets.
What makes Hugel a leader in the medical aesthetics industry?
Hugel is the first South Korean company to receive regulatory approvals in the three largest botulinum toxin markets, demonstrating its leadership and innovation.
How can I contact Hugel for more information?
You can reach out to Jihyun Kim via email at jihyun.kim@hugel-inc.com.
